The cross-priming pathway: a portrait of an intricate immune system
- PMID: 17386021
- DOI: 10.1111/j.1365-3083.2007.01909.x
The cross-priming pathway: a portrait of an intricate immune system
Abstract
Antigen presentation by professional antigen-presenting cells (pAPCs) to cytotoxic CD8(+) T cells can occur via two processing routes - the direct and cross-presentation pathways. Cross-presentation of exogenous antigens in the context of major histocompatibility complex (MHC) class I molecules has recently attracted a lot of research interest because it may prove crucial for vaccine development. This alternative pathway has been implicated in priming CD8(+) T-cell responses to pathogens as well as tumours in vivo (cross-priming). In cross-presentation, the internalized antigens can be processed through diverse intracellular routes. As many unresolved questions regarding the molecular basis that controls the cross-priming process still exist, it is essential to explore the various elements involved therein, to better elucidate this pathway. In this review, we summarize current data that explore how the source and nature of antigens could affect their cross-presentation. Moreover, we will discuss and outline how recent advances regarding pAPCs' properties have increased our appreciation of the complex nature of the cross-priming pathway in vivo. In conclusion, we contemplate how the direct and cross-presentation pathways can function to allow the immune system to deal efficiently with diverse pathogens.
Similar articles
-
Cross-presentation: underlying mechanisms and role in immune surveillance.Immunol Rev. 2005 Oct;207:166-83. doi: 10.1111/j.0105-2896.2005.00301.x. Immunol Rev. 2005. PMID: 16181335 Review.
-
Priming of T cells by exogenous antigen cross-presented on MHC class I molecules.Curr Opin Immunol. 2006 Feb;18(1):85-91. doi: 10.1016/j.coi.2005.11.003. Epub 2005 Dec 2. Curr Opin Immunol. 2006. PMID: 16326087 Review.
-
Mechanisms of MHC class I-restricted antigen processing and cross-presentation.Immunol Rev. 2005 Oct;207:145-57. doi: 10.1111/j.0105-2896.2005.00316.x. Immunol Rev. 2005. PMID: 16181333 Review.
-
Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentation by MHC class I molecules.Curr Opin Immunol. 2007 Feb;19(1):66-72. doi: 10.1016/j.coi.2006.11.017. Epub 2006 Dec 6. Curr Opin Immunol. 2007. PMID: 17157489 Review.
-
Dendritic cells use endocytic pathway for cross-priming class Ib MHC-restricted CD8alphaalpha+TCRalphabeta+ T cells with regulatory properties.J Immunol. 2009 Jun 1;182(11):6959-68. doi: 10.4049/jimmunol.0900316. J Immunol. 2009. PMID: 19454693
Cited by
-
Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.Mol Ther. 2019 Jul 3;27(7):1215-1227. doi: 10.1016/j.ymthe.2019.04.014. Epub 2019 Apr 19. Mol Ther. 2019. PMID: 31060789 Free PMC article.
-
Myeloid and Plasmacytoid Dendritic Cells and Cancer - New Insights.Open Access Maced J Med Sci. 2019 Oct 13;7(19):3324-3340. doi: 10.3889/oamjms.2019.735. eCollection 2019 Oct 15. Open Access Maced J Med Sci. 2019. PMID: 31949539 Free PMC article. Review.
-
Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.Cytokine Growth Factor Rev. 2021 Jun;59:101-110. doi: 10.1016/j.cytogfr.2021.01.001. Epub 2021 Jan 9. Cytokine Growth Factor Rev. 2021. PMID: 33593661 Free PMC article. Review.
-
Just one position-independent lysine residue can direct MelanA into proteasomal degradation following N-terminal fusion of ubiquitin.PLoS One. 2013;8(2):e55567. doi: 10.1371/journal.pone.0055567. Epub 2013 Feb 5. PLoS One. 2013. PMID: 23393593 Free PMC article.
-
HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.J Immunol. 2013 Aug 15;191(4):1567-77. doi: 10.4049/jimmunol.1300080. Epub 2013 Jul 12. J Immunol. 2013. PMID: 23851683 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials